KRRO
Korro Bio, Inc. · Healthcare · Market cap $136.8M
Insiders sold $5.4M net in the last 90 days ·6 sellers, 1 buyer· 13 of 18 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 15, 2026
Insider Buying
$20.8M
reported purchases (SEC code P)
Insider Selling
$5.7M
reported sales (SEC code S)
Unique Insiders
16
in the rolling window
Latest filing
Sep 15, 2026
FORMELA JEAN FRANCOIS
Korro Bio, Inc. (KRRO) has 37 SEC Form 4 filings (56 transaction rows) in the rolling window, disclosed by 16 distinct insiders. Most recent filing: Sep 15, 2026.
Inside the rolling window, 16 insiders at Korro Bio, Inc. reported 12 open-market purchases totaling $20.8M and 20 open-market sales totaling $5.7M. The most active filer is Director FORMELA JEAN FRANCOIS with 11 filings. Insiders have net sold $5.6M over the trailing 6 months. The most recent open-market filing is a sale of 10,200 shares by Director FORMELA JEAN FRANCOIS, dated Sep 11, 2026, worth $143K.
- Industry:Biotechnology
- CEO:Ram Aiyar
- Employees:57
- HQ:Cambridge, MA, US
- IPO:2019-10-03
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Director | Sale | 10,200 | $143K | Sep 15 | -34.0% | SEC ↗ | |
| Director | Sale | 38,490 | $543K | Sep 15 | -34.0% | SEC ↗ | |
| Senior Vice President, Finance | Sale | 5 | $69 | Sep 14 | -33.1% | SEC ↗ | |
| Senior Vice President, Finance | Sale | 7,347 | $99K | Sep 10 | -28.9% | SEC ↗ | |
| Senior Vice President, Finance | Sale | 6 | $82 | Sep 10 | -28.9% | SEC ↗ | |
| Director | Sale | 300 | $4K | Aug 28 | -28.0% | SEC ↗ | |
| Director | Sale | 28,468 | $399K | Aug 21 | -29.5% | SEC ↗ | |
| 10% Owner | Purchase | 5,222 | $60K | Aug 13 | — | SEC ↗ | |
| 10% Owner | Purchase | 1,462 | $19K | Aug 13 | — | SEC ↗ | |
| Director | Sale | 2,143 | $30K | Aug 13 | — | SEC ↗ | |
| President and CEO | Sale | 5,802 | $63K | Aug 5 | — | SEC ↗ | |
| Director | Sale | 100,700 | $1.4M | Jul 7 | — | SEC ↗ | |
| Director | Sale | 9,323 | $130K | Jul 7 | — | SEC ↗ | |
| Director | Sale | 3,962 | $55K | Jun 25 | — | SEC ↗ | |
| Director | Sale | 119,005 | $1.7M | Jun 25 | — | SEC ↗ | |
| Director | Sale | 48,438 | $707K | Jun 25 | — | SEC ↗ | |
Chappell ToddFirst filing | Chief Operating Officer | Sale | 3,168 | $34K | Jun 17 | — | SEC ↗ |
Dolan OliverFirst filing | Senior Vice President, Finance | Sale | 3,383 | $37K | Jun 17 | — | SEC ↗ |
Vincent Loic AFirst filing | Chief Scientific Officer | Sale | 3,418 | $37K | Jun 17 | — | SEC ↗ |
Cerio JeffreyFirst filing | General Counsel | Sale | 6,609 | $72K | Jun 17 | — | SEC ↗ |
Aiyar RamFirst filing | President and CEO | Sale | 15,152 | $197K | Jun 2 | — | SEC ↗ |
FORMELA JEAN FRANCOISFirst filing | Director | Sale | 2,860 | $40K | Jun 1 | — | SEC ↗ |
Lynx1 Capital Management LPFirst in 3 months | 10% Owner | Purchase | 520 | $6K | Apr 2 | — | SEC ↗ |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | — | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does KRRO have?
Korro Bio, Inc. (KRRO) has 37 SEC Form 4 filings (56 transaction rows) in the rolling 365-day window, disclosed by 16 distinct insiders. Most recent filing: Sep 15, 2026.
When was the most recent SEC Form 4 filing for KRRO?
The most recent Form 4 filing for KRRO on Tracefour is dated Sep 15, 2026.
Who is the most active insider at KRRO?
The most active SEC Form 4 filer at KRRO in the rolling window is Director FORMELA JEAN FRANCOIS, with 11 filings.
What is the net insider flow at KRRO over the last 6 months?
Over the trailing 180 days, insiders at KRRO have net sold $5.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at KRRO in the current window?
Inside the rolling window, insiders at KRRO bought $20.8M and sold $5.7M based on SEC Form 4 filings.
Can I get alerts for KRRO insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Korro Bio, Inc. (KRRO). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Korro Bio, Inc. is in the Healthcare sector.